Latest results FY2026 · Prices updated Oct 30, 2026
HQ: TokyoFounded 17814,808 employeesWebsite
A major Japanese pharmaceutical company. Focuses on gastroenterology, rare diseases, oncology, and neuroscience. Actively expanding its global presence.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Gastroenterology Business Unit | 33% | ¥1.4T | ¥0 | 0.0% |
| Plasma-Derived Therapies | 25% | ¥1.1T | ¥0 | 0.0% |
| Rare Disease Therapeutics | 18% | ¥762.7B | ¥0 | 0.0% |
| Oncology Business Unit | 14% | ¥580.1B | ¥0 | 0.0% |
| Neuroscience Business Unit | 10% | ¥414.3B | ¥0 | 0.0% |
Close (Oct 30, 2026)
¥6,651+57.1% (1Y)
Takeda +57.1% over 1Y, 46.2pt above the industry average (23 companies, +10.9%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥4.5T | ¥408.8B | ¥191.8B | ¥15.5T | -1.7% |
| 2025FY | ¥4.6T | ¥342.6B | ¥108.1B | ¥14.2T | +7.5% |
| 2024FY | ¥4.3T | ¥214.1B | ¥144.1B | ¥15.1T | +5.9% |
| 2023FY | ¥4.0T | ¥490.5B | ¥317.0B | ¥14.0T | +12.8% |
| 2022FY | ¥3.6T | ¥460.8B | ¥230.1B | ¥13.2T | +11.6% |
| 2021FY | ¥3.2T | ¥509.3B | ¥376.0B | ¥12.9T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
